BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.00B |
| Revenue (ttm) | 188.03M |
| Net Income (ttm) | -193.97M |
| Shares Out | 185.58M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,539,189 |
| Open | 10.25 |
| Previous Close | 10.17 |
| Day's Range | 10.19 - 10.91 |
| 52-Week Range | 7.61 - 19.99 |
| Beta | 2.51 |
| Analysts | Buy |
| Price Target | 17.80 (+65.4%) |
| Earnings Date | Aug 4, 2022 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 in... [Read more...]
Financial Performance
In 2021, BCRX's revenue was $157.17 million, an increase of 782.38% compared to the previous year's $17.81 million. Losses were -$184.06 million, 0.68% more than in 2020.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 17.8, which is an increase of 65.43% from the latest price.
News
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunolo...
RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and ...
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
RESEARCH TRIANGLE PARK, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma Gmb...
Why BioCryst Pharmaceuticals Topped the Market Today
The company receives some good news from a top regulator.
FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250
RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designati...
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention ...
RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) fo...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference in New ...
Why BioCryst Stock Lost Nearly 4% of Its Value Today
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
—Q1 2022 ORLADEYO net revenue of $49.7 million—
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 23 n...
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why BioCryst Stock Shot Nearly 5% Higher Today
The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.
BioCryst to Report First Quarter 2022 Financial Results on May 5
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thurs...
After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?
Things aren't actually that bad.
Why BioCryst Pharmaceuticals Stock Sank Today
Another analyst gets notably less enthusiastic about the company's prospects.
Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
Investors returned to the stock after last week's sell-off.
Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
Why BioCryst Pharmaceuticals Stock Is Falling
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target. BofA Securities analyst Tazeen A...
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthcare...
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not...
Why BioCryst Pharmaceuticals Stock Is Crashing Today
The company is pausing patient enrollment in three clinical studies.